Autologous tumor infiltrating lymphocytes (TIL) therapy

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONRC-14004713

Enrollment

Unknown

Registered

2014-05-27

Start date

2014-05-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

TIL group:TIL

Control Group:TIL

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with malignant pathology or cytology confirmed; Non-pregnant and lactating patients; No allergic reactions for biological products

Exclusion criteria

Exclusion criteria: Obviously the heart and liver and kidney dysfunction, vital organs functioning properly; Serious cardiovascular and cerebrovascular diseases, diabetes; Serious viral, bacterial infection (infection in patients with fever of taboos - except tumor heat); History of organ transplantation and autoimmune diseases; T-cell lymphoma and leukemia patients contraindicated

Design outcomes

Primary

Measure	Time frame
quality of life of patients;TIL safety;overall surviva;	—

Countries

China

Contacts

Public ContactTian Geng

Shenzhen Second People's Hospital

tiangeng666@aliyun.com+86 13724395569

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026